Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR.
| Image |  |
|---|---|
| Description | scientific article published on 08 January 2014 |
| Author/s |
author: Gary C Starling |
| Publication date | January 8, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |